Article

Posterior chamber phakic ICL a valuable option for moderate to high myopia

Author(s):

Cheryl Guttman

San Francisco-Three-year FDA clinical trial outcome data support the safety, efficacy, and predictability of the Implantable Contact Lens (ICL, STAAR Surgical) for the treatment of moderate to high myopia, said Stephen G. Slade, MD, at the American Society of Cataract and Refractive Surgery annual meeting.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
Q&A: Meeting the need for low vision services with wearable tech
June 19th 2025

Q&A: Meeting the need for low vision services with wearable tech

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image credit: AdobeStock/Justlight)
June 18th 2025

Ruth Hogg, PhD, on what retinal imaging can tell clinicians about the brain and body

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Ocular Therapeutix to present at Clinical Trials at the Summit 2025
June 18th 2025

Ocular Therapeutix to present at Clinical Trials at the Summit 2025

Johnson & Johnson launches TECNIS Odyssey IOL in Europe, Middle East, and Canada
June 18th 2025

Johnson & Johnson launches TECNIS Odyssey IOL in Europe, Middle East, and Canada

© 2025 MJH Life Sciences

All rights reserved.